drugset / Trial / NCT00195312

Study Evaluating Vaccine in Adults With HIV

NCT00195312

Phase 1 Terminated 91 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV. A second purpose for this study is to understand how your immune system responds to the study vaccine with the adjuvants. Understanding these differences could be useful in several ways. First, it might help identify people whose disease is likely to respond to the study vaccine with the study adjuvants. Second, the information might be useful in developing other treatments for people whose disease does not respond to the study vaccine with the adjuvants.

Timeline

Start
2005-08
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HIV-1 gag DNA Vaccine
Subject IL-12 DNA Vaccine
Subject IL-15 DNA Unknown
Background Bupivacaine Other / unclassified